

# Adaptation of Remote Symptom Monitoring Using Electronic Patient-Reported Outcomes for Implementation in Real-World Settings

Gabrielle B. Rocque, MD, MSPH<sup>1,2,3</sup>; D'Ambra N. Dent, BA<sup>1</sup>; Stacey A. Ingram, MEd<sup>1</sup>; Nicole E. Caston, MPH<sup>1</sup>; Haley B. Thigpen, BS<sup>1</sup>; Fallon R. Lalor, BS<sup>1</sup>; Omer H. Jamy, MD<sup>1,3</sup>; Smith Giri, MD, MSPH<sup>1,3</sup>; Andres Azuero, PhD<sup>4</sup>; Jennifer Young Pierce, MD, MPH<sup>5</sup>; Chelsea L. McGowen, MPH<sup>5</sup>; Casey L. Daniel, PhD, MPH<sup>5</sup>; Courtney J. Andrews, PhD<sup>5</sup>; Chao-Hui Sylvia Huang, PhD<sup>2</sup>; J. Nicholas Dionne-Odom, PhD, RN<sup>4,2</sup>; Bryan J. Weiner, PhD<sup>7</sup>; Doris Howell, PhD<sup>8</sup>; Bradford E. Jackson, PhD<sup>9</sup>; Ethan M. Basch, MD<sup>9</sup>; and Angela M. Stover, PhD<sup>9,10</sup>

**QUESTION ASKED:** Remote symptom monitoring facilitated by electronic patient-reported outcomes has demonstrated clinical benefits in efficacy within randomized clinical trials; however, experience with implementation in real-world settings is limited. In this manuscript, we assess what are the core components and barriers requiring adaptations for implementation of remote symptom monitoring using electronic patient-reported outcomes in real-world settings.

**SUMMARY ANSWER:** Core components of remote symptom were documented. Adaptations were identified to address barriers related to workflow challenges, patient and clinician access to technology, digital health literacy, survey fatigue, alert fatigue, and data visibility.

**WHAT WE DID:** This formative evaluation assessed core components and adaptations to improve acceptability and fit of remote symptom monitoring using Stirman's Framework for Modifications and Adaptations. Implementation outcomes were evaluated in pilot studies at the two cancer centers testing technology (phase I) and workflow (phase II and III) using electronic health data; qualitative evaluation with semi-structured interviews of clinical team members; and capture of field notes regarding barriers and recommended adaptations for future implementation.

**WHAT WE FOUND:** In the pilot studies, most patients completed > 50% of expected surveys. From pilot work, the following core components of remote symptom monitoring were identified: electronic delivery of surveys with actionable symptoms, patient education on the intervention, a system to monitor survey compliance in real time, the capacity to generate alerts, training nurses to manage alerts, and identification of responsible personnel. Key adaptations to enhance feasibility and acceptability of implementation are shown in the table.

**BIAS, CONFOUNDING FACTOR(S), REAL-LIFE IMPLICATIONS:** This study was conducted at two academic medical centers; other sites may differ in their institutional culture, staffing expectations, implementation readiness, and individual barriers experienced. Additionally, this study focused on early adaptation of remote symptom monitoring and does not capture adaptations that are made to maintain a well-established program. Using an implementation science approach, we facilitated adaptation of remote symptom monitoring interventions from the research setting to clinical practice and identified key areas to promote effective uptake and sustainability.

## CORRESPONDING AUTHOR

Gabrielle B. Rocque, MD, MSPH, University of Alabama at Birmingham, 849 Boshell Bldg 1808 7th Ave, South Birmingham, AL 35294; e-mail: [grocque@uabmc.edu](mailto:grocque@uabmc.edu).

Author affiliations and disclosures are available with the complete article online.

Accepted on September 12, 2022 and published on October 28, 2022:

Full-length article available online at DOI <https://doi.org/10.1200/OP.22.00360>



# Adaptation of Remote Symptom Monitoring Using Electronic Patient-Reported Outcomes for Implementation in Real-World Settings

Gabrielle B. Rocque, MD, MSPH<sup>1,2,3</sup>; D'Ambra N. Dent, BA<sup>1</sup>; Stacey A. Ingram, MEd<sup>1</sup>; Nicole E. Caston, MPH<sup>1</sup>; Haley B. Thigpen, BS<sup>1</sup>; Fallon R. Lalor, BS<sup>1</sup>; Omer H. Jamy, MD<sup>1,3</sup>; Smith Giri, MD, MSPH<sup>1,3</sup>; Andres Azuero, PhD<sup>4</sup>; Jennifer Young Pierce, MD, MPH<sup>5</sup>; Chelsea L. McGowen, MPH<sup>5</sup>; Casey L. Daniel, PhD, MPH<sup>5</sup>; Courtney J. Andrews, PhD<sup>6</sup>; Chao-Hui Sylvia Huang, PhD<sup>2</sup>; J. Nicholas Dionne-Odom, PhD, RN<sup>4,2</sup>; Bryan J. Weiner, PhD<sup>7</sup>; Doris Howell, PhD<sup>8</sup>; Bradford E. Jackson, PhD<sup>9</sup>; Ethan M. Basch, MD<sup>9</sup>; and Angela M. Stover, PhD<sup>9,10</sup>

## abstract

**PURPOSE** Despite evidence of clinical benefits, widespread implementation of remote symptom monitoring has been limited. We describe a process of adapting a remote symptom monitoring intervention developed in a research setting to a real-world clinical setting at two cancer centers.

**METHODS** This formative evaluation assessed core components and adaptations to improve acceptability and fit of remote symptom monitoring using Stirman's Framework for Modifications and Adaptations. Implementation outcomes were evaluated in pilot studies at the two cancer centers testing technology (phase I) and workflow (phase II and III) using electronic health data; qualitative evaluation with semistructured interviews of clinical team members; and capture of field notes from clinical teams and administrators regarding barriers and recommended adaptations for future implementation.

**RESULTS** Core components of remote symptom monitoring included electronic delivery of surveys with actionable symptoms, patient education on the intervention, a system to monitor survey compliance in real time, the capacity to generate alerts, training nurses to manage alerts, and identification of personnel responsible for managing symptoms. In the pilot studies, while most patients completed > 50% of expected surveys, adaptations were identified to address barriers related to workflow challenges, patient and clinician access to technology, digital health literacy, survey fatigue, alert fatigue, and data visibility.

**CONCLUSION** Using an implementation science approach, we facilitated adaptation of remote symptom monitoring interventions from the research setting to clinical practice and identified key areas to promote effective uptake and sustainability.

JCO Oncol Pract 18:e1943-e1952. © 2022 by American Society of Clinical Oncology

## INTRODUCTION

Remote symptom monitoring facilitated by electronic patient-reported outcomes (ePROs) has demonstrated clinical benefits in multiple efficacy randomized clinical trials.<sup>1-3</sup> In the pivotal trial by Basch et al, patients with metastatic solid tumors receiving remote symptom monitoring experienced significantly improved symptom control, quality of life, length of time on treatment, hospitalization rates, and overall survival when compared with standard of care.<sup>1,2</sup> Similarly, Denis et al conducted a randomized clinical trial of patients with lung cancer randomly assigned to ePRO remote symptom monitoring versus standard of care, observing a substantial significant median survival benefit to remote symptom monitoring.<sup>3</sup> These studies led to the development of the PRO-TTECT trial that implemented ePROs in 26 community oncology

practices.<sup>4</sup> The intervention was well received: 79% of nurses reported information was helpful in documentation, 84% noted increased efficiency of patient discussions, and 75% reported the information was useful for patient care. Furthermore, 91% of oncologists found the ePRO information useful and 65% used ePROs in decision making.<sup>4</sup> On the basis of this encouraging evidence, incorporation of ePROs, such as remote symptom monitoring, is included as a practice transformation activity for Medicare's Enhanced Oncology Model<sup>5</sup> and in the Oncology Medical Home standards released jointly by American Society of Clinical Oncology and the Community Oncology Alliance.<sup>6</sup>

However, widespread implementation of remote symptom monitoring with ePROs has been limited and remains an underutilized resource outside of highly

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on September 12, 2022 and published at [ascopubs.org/journal/op](https://ascopubs.org/journal/op) on October 28, 2022; DOI <https://doi.org/10.1200/OP.22.00360>

controlled research trials. In real-world settings, barriers exist for implementation at technical and workflow levels (eg, time constraints and interpretation of data).<sup>7</sup> It is important to maintain core components of interventions, which are the functions or principles necessary to provide the desired outcomes.<sup>8</sup> At the same time, adaptations are inevitably needed for integration into standard of care. Adaptations are specific, planned, and purposeful *changes to the intervention* that enhance acceptability and fit to a local context.<sup>8</sup> Documentation of core components and adaptations for successful implementation are essential to support scale up and spread efforts. The objective of this study is to describe the core components of our remote symptom monitoring intervention, the process of adapting this intervention for uptake in real-world settings, and key adaptations made to facilitate acceptability and fit for use in routine clinical practice.

## METHODS

### Design

This formative evaluation assessed core components and adaptations to improve acceptability and fit of remote symptom monitoring using Stirman's Framework for Modifications and Adaptations. Formative evaluation includes strategic modification of interventions before implementation into practice.<sup>9</sup> Our formative evaluation included three phases. In phase I, the primary goal was to assess barriers to use of the technology platform (Carevive, Boston, MA) used to deliver the remote symptom monitoring intervention. In phase II, the primary goal was to identify workflow barriers and adaptations. Phase III included early implementation of implementation across all cancer types, during which additional adaptations were made. The duration of patient engagement was 6 weeks, 3-6 months, and 6 months for phase I, II, and III, respectively. This work was approved by the University of Alabama at Birmingham (UAB) Institutional Review Board for phases I-III and the University of South Alabama for phase III. Staff informal consent was implied by participation in interviews. All ePROs were implemented as standard of care, thus patients did not provide informed consent. Adaptations were made and tracked as part of a quality improvement initiative.

### Setting

This study was conducted at the UAB and at the University of South Alabama Mitchell Cancer Institute (MCI). UAB and MCI are located in Alabama, which has a large number of census block groups with high area deprivation index scores, reflecting the low socioeconomic status of the state.<sup>10</sup> These institutions serve a population that includes 25% Black patients, 30% rural residents, and 10% of people who are socioeconomically disadvantaged (dual eligible for Medicare and Medicaid). UAB and MCI are the only two academic medical centers in Alabama.

### Remote Symptom Monitoring Intervention

The remote symptom monitoring intervention implemented at UAB and MCI is consistent with the evidence-based intervention shown to be effective by Basch et al<sup>1,2</sup> and consistent with the European Society of Medical Oncology clinical practice guidelines.<sup>11</sup> Our process includes a navigator or care coordinator explaining the rationale for remote symptom monitoring to patients and guiding them through the technical aspects of enrollment and participation (eg, setting up an account and how to complete surveys). Patients complete a weekly remote symptom assessment using the ePRO version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE; Fig 1).<sup>12</sup> If a patient reports one or more symptoms meeting a predefined threshold or a change in symptoms are reported, an automated alert is sent to a nurse who calls the patient, coordinates care, and communicates with the physician as needed. Data from remote symptom monitoring are available for clinicians in clinic as part of a dashboard in the electronic health record (EHR) for treatment decisions.

### Integration Into the Electronic Medical Record

To facilitate workflow, remote symptom monitoring was increasingly integrated in the EHR over the course of the three phases. In phase I, a link to the technology platform was included in the EHR. In phase II, the dashboard was integrated in the patient's individual record and alert features were modified to alert as a result within the message center inbox of the nurse designated to respond to the alert to each patient. In phase III, additional minor modifications were made to data visibility and alert closure options.

### Process for Identifying Core Components

The team that conducted the randomized clinical trials (E.M.B. and A.M.S.) reviewed the detailed protocols from the trials<sup>1,2</sup> and the intervention deployed as part of this implementation. The intervention developers identified core components necessary for fidelity, which were reviewed with the implementation team and documented.

### Implementation Science Frameworks

The updated Framework for Modifications and Adaptations (FRAME) by Stirman et al provides a robust mechanism for reporting on adaptations to the intervention that occur in the implementation process. This framework includes eight components, which are used to characterize recommended adaptations: (1) when and how in the implementation process the modification was made, (2) whether the modification was planned, (3) who determined the modification should be made, (4) what was modified, (5) at what level of delivery the modification was made, (6) type or nature of context- or content-level modifications, (7) whether the modification was fidelity-consistent, and (8) reasons for the modification.<sup>13</sup> We tracked these modifications in real time.




FIG 1. Process for identifying and implementing intervention adaptations.

### Process for Adaptation

The adaptation process is shown in Figure 1. Step 1 includes both formal and informal evaluation of remote symptom monitoring implementation. Step 2 involved reviewing feedback with the implementation team. Any potential modifications were reviewed with relevant key partners (step 3) and cross-referenced with the intervention developers (Principle Investigator of the randomized trials) when needed (step 4). When consensus was reached, the adaptation was made and documented (step 5). Finally, the implementation team regrouped with key partners to assess whether the adaptation addressed the intended barrier (step 6). Key adaptations from the pilots and early standard-of-care implementation are described using FRAME.

### Formative Evaluation

**Quantitative evaluation.** Quantitative evaluation conducted during pilot studies (phase I and phase II) included review of patient demographics and implementation outcomes.<sup>14</sup> These outcomes included service penetrance (% of patients agreeing to participate in the pilot studies), compliance (% of surveys completed), completion (% of questions completed within opened surveys), and provider adoption (% alert closure).<sup>15</sup> Implementation outcomes were calculated from data abstracted from the EHR and focused on feasibility and acceptability.

**Qualitative evaluation.** Qualitative evaluation was conducted using semistructured interviews with nurse navigators (ie, care coordinators), physicians, and administrative leaders between phase I and phase II. All participants provided

informed consent. Interviews were audio-recorded, transcribed verbatim, and deidentified. Using content analysis,<sup>16</sup> the study Principle Investigator (G.R.) and two medical students (H.B.T. and F.R.L.) independently coded using an inductive coding approach to identify barriers, facilitators, and recommended adaptations to remote symptom monitoring that would increase acceptability or fit of the intervention using NVivo. All three coders reviewed and discussed themes and exemplary quotes until consensus was reached.

In addition to the formal evaluation, the implementation team captured clinical team and administrator feedback on barriers and suggested adaptations as informal field notes throughout the course of all three implementation phases. Field notes included discussions occurring during and between clinical team meetings in the form of verbal feedback. Field notes were reviewed for key themes by the investigative team.

## RESULTS

### Identification of Core Components

The results of the analysis identifying core components of remote symptom monitoring with ePROs in original efficacy and effectiveness research evaluation are shown in Table 1. Although a flexible system that allows for multiple modalities to collect surveys is ideal, the surveys should be able to be completed at home. Remote symptom monitoring should be delivered electronically to enable efficient survey administration and prompt reporting to the clinical team. Furthermore, ePRO symptom monitoring that is integrated into the EHR optimizes the workflow and visibility of the data.

Another core component to implementation is the patient's introduction and orientation to the ePRO system as a routine standard of care, which is reinforced on follow-up encounters as needed. The symptoms evaluated in remote symptom monitoring should be actionable, with available clinical responses to manage symptoms. Although some systems can only deliver surveys in clinic, which still has potential for improving communication about symptoms, maximal benefit is observed when remote delivery is available to capture symptoms between clinic visits. Given the nature of home-based interventions, a system must be in place to monitor survey compliance in real time for incomplete surveys and provide outreach to those patients. This typically includes automated reminders followed by a phone call with the option for patients to complete assessments over the phone. Finally, the system must have the capacity to generate automated alerts, and a designated clinician must assume responsibility for monitoring alerts and engaging with the patient to provide appropriate support.

### Adaptations

**Formal quantitative evaluation (phase I).** Phase I was administered from September 2019 to November 2019, during which 23 patients with lymphoma, breast, gastrointestinal, and genitourinary cancers were approached for

participation; of these, 40% self-reported an Eastern Cooperative Oncology Group performance status of  $\geq 3$  (confined to bed or chair  $\geq 50\%$  of waking hours). Three patients declined participation, yielding a service penetrance of 87%. Of the 20 participants who participated, 70% completed all surveys; 15% completed 50%-99% of surveys during a 6-week period. Only 15% of patients completed  $< 50\%$  of surveys (compliance). Of 368 symptoms reported, 20% included a severe symptom alert.

**Qualitative evaluation (between phase I and II).** Physicians ( $n = 5$ ), nurses/nurse navigators ( $n = 5$ ), and administrative leaders ( $n = 2$ ) participated in interviews about barriers, facilitators, and recommended adaptations after phase I. The FRAME was used to document specific components of the adaptation process garnered from interviews.<sup>13</sup> No substantial technical difficulties were reported (eg, surveys not reaching patient and nurses unable to electronically close alerts). The clinical teams identified key facilitators regarding perceived benefit and supports for the intervention, including recognition that the intervention provided crisis prevention and enhanced patient outcomes, improved identification of symptoms, supported patient self-management of less severe symptoms, and monitored trends over time, and was integrated into the EHR (Table 2).

**TABLE 1.** Core Components of the Remote Monitoring Intervention Identified for Effective Electronic Data Capture, Clinical Integration, and Patient Engagement

Domain	Implementation Concept	Detail
Electronic data capture	Core component	Electronic system to deliver surveys
		Electronic approach to analyze survey compliance
		Electronic capture of alert management responses
	Facilitators	Alert integration into the EHR
		Including a dashboard in the EHR that displays symptoms
		Integration into clinic notes
Clinical integration	Core component	Integration of program into clinical workflow
		Surveys include standardized questionnaires with scientific rationale
		Surveys include clinically actionable symptoms
		System can generate alerts to responsible individual
		Implementation should be done within context of quality improvement
	Language included for medical-legal coverage	
	Facilitators	Reminders for clinical teams to reach out for incomplete surveys
	Patient engagement	Core component
Repeated messaging that the program is central to patient management		
Parsimonious surveys		
Facilitators		Patient reminders to complete surveys
		Free text option for other symptoms
		Pop-up summary of symptoms that will alert upon survey completion
		Link to prompt that takes patient directly to questions
Lack of password for login		

Abbreviation: EHR, electronic health record.

At the same time, the clinical teams identified barriers, with associated suggestions for improvement (Table 3). The nurses expressed frustration about having to call patients about completing surveys, as this was felt to be practicing below their nursing license. Furthermore, they were also concerned about the number of surveys the institution administered to patients in general (eg, satisfaction surveys and surveys about handwashing). The nurses also reported concerns about patients who had alerts that were not felt to be actionable. For example, fatigue was common (25% of surveys), yet the nurses did not feel they had available interventions for fatigue. Additionally, they noted some patients reported severe symptoms for chronic pain, yet when the nurses called, the patient stated the pain was chronic and managed with medications or was not related to their cancer. Finally, physicians commented that they were not adequately engaged since the alerts did not come to them and requested more visibility of the data and integration into the EHR.

**Formal quantitative evaluation (phase II).** In myeloma and acute leukemia phase I pilots, 47 eligible patients were approached by research assistants who function as lay navigators; 35 patients agreed to participate in a 3-month remote symptom-monitoring program (74% service penetration). Patients included both new patients and patients already on treatment. Of patients with acute leukemia and myeloma, 89% and 82% of all surveys administered were opened, respectively. The majority of participants were age 60–74 years (80%); 20% were age 75 years or older. Average rate of completion of surveys opened for patients with acute leukemia was 94% and for patients with myeloma

was 92%. Of 294 symptoms reported, 70% included a severe symptom alert. All alerts were closed at study completion, although time to closure was not captured (provider adoption).

**Field notes-clinical teams (phase II-III).** All additional feedback provided by the clinical teams was captured as field notes in real time and integrated into the FRAME table for recommended adaptations. The research assistants expressed concerns over variability in the education about the program to patients and completion of the intake process needed to start surveys, given multiple steps in the patient enrollment. They requested a more automated, streamlined approach, such as a video that walked patients through the enrollment process. Among the nurses, there were concerns about alert fatigue and who was the most appropriate person to respond to alerts. For example, many patients with leukemia completed surveys initially in the inpatient setting, but the outpatient nurse identified as responsible for managing alerts did not believe she was the appropriate person to receive this information when she was not managing inpatient care. The clinic nurses also shared the concerns about chronic symptoms where patients when called stated that they wanted to report without desiring a callback about the symptom.

**Field notes-administrators (before phase III).** When considering plans for health system-wide rollout, the cancer center administration felt that limiting remote symptom monitoring to only those with advanced-stage cancer would be challenging because of difficulty discerning who

**TABLE 2.** Perceived Benefits and Facilitators for Remote Symptom Monitoring of Phase I Participants

Benefits and Facilitator Themes	Quotes
Provides crisis prevention and improved patient outcomes	"I think it will impact [ER admissions] in a good way for those high-risk patients that we know have the potential to have to visit the ED. If the nurse navigator was proactive with sending them a survey and keeping a close eye on symptoms, encouraging them to complete the surveys on time... and the patient still goes to the ER, I think it's a great tool because our physicians will be able to see that document in Cerner...so it would kind of prompt them to look at other measures or contact the on-call fellow that's working with oncology too. I think that it would overall be very beneficial for our ER patients, especially those that are frequent visitors or that are at high risk." (nurse)
Improves identification of symptoms	"I have found it useful in my conversations with patients, to be able to say, "I see that you're still having pain at home, are you taking your pain medicines?", to try to do some reinforced education based on their home monitoring. I've definitely also had some encounters where the nurses have called me about issues that they've identified with patients that they haven't necessarily brought up in clinic, which has been very helpful for patients." (physician)
Supports patient self-management of less severe symptoms	"I think it's just an educational process that, over time, you hope that you are able to move even the patient from a novice to an expert. To be able to manage and engage and do some self-care management." (administrative leadership)
Monitors trends	"I do think, as this becomes more standardized, being able to see these trends over time, and see if somebody's been stable, stable, stable for a couple of months and then boom, they have a new problem, I think that's going to allow us to be much more proactive in terms of our management." (physician)
Integrates into the electronic health record	"I think it's a great tool because our physicians will be able to see that document in Cerner and can without having to talk to someone in the clinic, say for instance it's after hours or weekends, they can pull up that document and see, "Oh well she has been complaining of this for X amount of days and this is what the clinic implemented to assist with that." (nurse)

Abbreviations: ED, emergency department; ER, emergency room.

**TABLE 3.** Examples of Key Barriers and Recommended Adaptations for Remote Symptom Monitoring Implementation

Barrier Themes	Quotes	Suggestion Themes	Quotes
Workflow issues	“I think the biggest bulk of the work for this project is on those nurse coordinators who are the primary point of contact for the patients doing this, so I do think that it is a little challenging for them, in terms of workflow. Little bits of information that I’ve heard, just from them, is they struggle a little bit with making sure that the surveys are done.” (physician)	Clear delineation of staff roles	“Clearly delineating between visit staff being the coordinators and then the in-clinic visit staff being the clinic nurses, I think is the best delineation. The supervisor of everybody has done a really beautiful job pulling together what are roles and responsibilities of these different groups, the navigator, the nurse coordinator, and the clinic nurse, and I think that’s really helpful to just have that written out on paper.” (physician)
Staff frustration with incomplete surveys	“And I think there was one older patient that I did sign up, and he did not do any of the surveys. And when I tried to call him to remind him, he’d never returned my calls. He is a member of the portal and would send me portal messages if anything was wrong with him, but if I sent him a portal message asking him about the surveys, he never would reply to me.” (nurse)	Assign role of managing alerts and reminders to different people	“In the next phase, I anticipate we will be bringing in our lay navigators to take the volume of work that’s associated with getting patients signed up and making sure that the surveys get done and calling and checking on them if they haven’t been done.” (physician)
Patient access to internet and cell phones	“Now, that being said, we will have other challenges: cellular reception or Wi-Fi is going to be an issue. We’ve talked a little bit about what do we do for patients that don’t have a smartphone, for example.” (physician)	Provide smartphones to patients	“I know at [cancer center], they do some kind of similar telephone based outreach in [region of the country] and they have gotten [cellular service] to provide free cell phones for patients that basically can’t afford one, and the institution covers that first year of service, but that allows them to provide support to those patients who otherwise really are very likely to fall through the cracks. So, I could see us doing something like that here.” (physician)
Digital health literacy	“Right now, in the pilot study, we’re targeting that older population who has not been formally educated on how to use the tool. So, a lot of times, they just don’t pay attention to somebody sending them a text or reminder of any sort.” (nurse)	Educate patients on how to complete surveys and their importance	“A lot of times they’re just intimidated by technology. But if there’s somewhat of an educational component in there where we actually sit down... with them and teach them how to use the tool. Then I think they’d be more comfortable with it.” (nurse)
Survey fatigue	“There are a lot of people doing different things at different times. You know, our research group is actually doing some. I already know that The Oncology Care Model is also separately doing some. So certain of our patients may have had a lot of these [surveys].” (physician)	Customization of surveys	“I think having some customization of the surveys to have it smartlogic to say, “If you’re this type of cancer patient and you’ve had these symptoms, we’re going to ask you these questions,” whereas right now, everybody’s getting the same questions... I could imagine also just simplifying the survey too, like if you haven’t had any symptoms for four weeks in a row, maybe you space out the surveys, so eventually I would love to see some kind of Smartlogic built into the surveys so that it’s more adapted to that patient and that patient experience and we’re not overburdening them with surveys.” (physician)
Alert fatigue	“I have found with one of my patients that reports a severe symptom every week, it’s not related to her cancer.” (nurse)	Add an option to mark that the symptom is chronic or not cancer-related	“It would be nice if this is to continue, that there’d be an option for them to indicate not related to cancer, not related to my cancer diagnosis.” (nurse)

had advanced-stage versus early-stage cancer and may not capture all those in need of the intervention. Instead, cancer center administration elected to move forward with all patients on active chemotherapy, immunotherapy, or targeted therapies. Given that patients could be on treatment for an extended duration, the decision was made to administer surveys for 6 months only for each patient if

they remained on the same treatment or transitioned to survivorship, instead of the 12 months used in prior randomized control trials.<sup>4</sup> If they started a new therapy, they reinitiated surveys for another 6 months. This approach aligned with the 6-month episodes in Medicare’s episode-based payment approach of the Oncology Care Model.<sup>17</sup>

**TABLE 4.** Identified Adaptations for Effective Implementation of Remote Symptom Monitoring Using the Framework for Modifications and Adaptations

Reasons for Modification	Who Suggested Modification	Was the Modification Planned	What Was Modified; Context	Level of Delivery the Modification Was Made	Whether Modification Is Fidelity-Consistent <sup>a</sup>	When in the Process Were Modifications Made
Workflow challenges	Implementation team	Proactive	Inclusion of patients with early-stage and metastatic cancer	All levels	Consistent	Before phase II
	Implementation team	Proactive	Defined time for surveys as 6 months	All levels	Consistent	Before phase II
	Implementation team	Proactive	Formalized assignment of survey initiation and compliance to navigators; alert response to clinic nurses	Navigator level, nursing level	Consistent	Before phase II
	Technology team	Proactive	Automated patient reminders before sending reminder for navigator to call patients for overdue surveys	Navigator level	Consistent	Before phase II
	Technology team and research assistants serving in navigation role	Proactive	Added a self-enrollment video that educates patients on the program and how to participate	Navigator level	Consistent	During phase II
	Nurse lead	Reactive	Added attempted to call as choice to close alerts to capture unsuccessful efforts	Nursing level	Consistent	During phase III
	Nurse lead	Reactive	Allowed patients to select survey delivery on days preferred by their clinic nurse (eg, not on off days nor Fridays)	Nursing level	Consistent	During phase III
Alert fatigue	Nursing leadership	Reactive	Removed fatigue; added urinary problems	All levels	Consistent	Before phase III
	Technology team	Reactive	Added a snooze option by setting expected alert threshold for up to 4 weeks	Nursing level	Consistent	Before phase III
	Implementation team	Reactive	Deferred start time to after hospital discharge; added question about location so nurses can close alerts for inpatients who have daily contact with clinical teams	Nursing level	Consistent	Before phase III
Alert fatigue; survey fatigue	Implementation lead	Reactive	Allowed patients to indicate that they do NOT want a call about their symptoms	Nursing level	Consistent	During phase III
Data visibility	Implementation team	Proactive	Developed smart template for inclusion of symptoms and alerts in physician note templates	Physician level	Consistent	Before phase III
	Technology team	Proactive	Developed dashboards of patient-reported data	Physician level; nursing level	Consistent	Before phase II

<sup>a</sup>Consistency was defined as not conflicting with core components defined to ensure fidelity (adaptations differ from original intervention).



**Summary of adaptations.** Using this formative evaluation, the implementation team made adaptations to the program to prepare for and address challenges encountered across UAB and MCI. These adaptations, categorized using FRAME, addressed barriers related to workflow challenges, alert fatigue, and data visibility (Table 4).

## DISCUSSION

This study identified adaptations to overcome barriers to implementing research-tested, evidence-based remote symptom monitoring with ePROs into real-world clinical settings. The barriers targeted by these adaptations are similar to barriers encountered in other remote symptom monitoring programs. For example, in the broad rollout within the Texas Oncology community oncology multisite practice by Patt et al,<sup>18</sup> they highlighted challenges related to ePRO completion compliance and lack of reminder text or e-mail prompts for patients not completing surveys. In another evaluation of home symptom monitoring for patients with head and neck cancers, key barriers included the energy, time, and motivation needed from team members for implementation, the needed workplace adjustments, and the need of technical support.<sup>19</sup> Although these studies suggested barriers that are similar to those noted in our evaluation, they did not specifically include planned or actual adaptations to address these challenges as is done in this manuscript. Given the call to implement remote symptom monitoring broadly in oncology,<sup>5,6</sup> it is warranted not only to describe barriers, but also to show how institutions can approach adaptation to the intervention developed in randomized clinical efficacy trials, while maintaining fidelity to the intervention.

Although the adaptations themselves are anticipated to be beneficial for future implementation, this manuscript also provides an approach to adaptation that can be modeled when implementing complex, multilevel interventions in general. It is beneficial to capture both formal programmatic evaluations, as well as field notes, because both influence decisions for modifying and implementing the intervention.

Often, the ongoing dialogue amongst the implementation team and rationale for change between formal evaluations is not well captured, which limits the understanding of the adaptation process. We recommend assigning responsibility of field-note-taking to a member of the implementation team

during both formal meetings and ad hoc communication. In addition, use of a more structured approach to decision making, as noted in Figure 1, can ensure that relevant key partners are included in the process and that adaptations to the intervention are communicated effectively. Finally, health care systems *must* recognize the iterative nature of adaptation and that this process requires continued maintenance to prevent unwanted programmatic drift that affects fidelity. As such, we recommend reviewing modifications at least quarterly to ensure a standard approach across disease sites. We acknowledge that this does take time and resources to complete both initial data capture and review of materials, but is critical for understanding the evolution of changes to interventions and implementation processes. As such, we recommend at least one project manager to support the implementation, facilitate key partners engagement, and enact needed changes.

This study has several limitations. We describe the adaptation process and key adaptations for two centers located in the Southern United States. Other sites may differ in their institutional culture, staffing expectations, implementation readiness, and individual barriers experienced. However, on the basis of the joint experience of the two participating sites and commonality with prior literature on barriers, we do anticipate that barriers encountered in these initial three phases are not unique to these practices. This study included a limited number of providers, thus additional insights may be gained with more participants. Additionally, this study focused on early adaptation of remote symptom monitoring and does not capture adaptations that are made to maintain a well-established program. We did not explicitly capture the time spent on reviewing the intervention, selecting adaptations, or implementing changes. Future work will be required to assess adaptations for sustainability. In addition, ongoing evaluation is being conducted to formally capture patient perspectives and describe implementation strategies (eg, use of physician champions, audit, and feedback).

In conclusion, adaptations to the intervention of remote symptom monitoring with ePROs developed in efficacy clinical trials are needed to facilitate effective standard of care implementation. The use of formative evaluation to guide the adaptation process provides a mechanism for selecting appropriate key intervention components and adaptations to enhance fit and acceptability.

## AFFILIATIONS

<sup>1</sup>University of Alabama at Birmingham, Department of Medicine, Division of Hematology and Oncology, Birmingham, AL

<sup>2</sup>University of Alabama at Birmingham, Department of Medicine, Division of Gerontology, Geriatrics, and Palliative Care, Birmingham, AL

<sup>3</sup>O'Neal Comprehensive Cancer Center, Birmingham, AL

<sup>4</sup>University of Alabama at Birmingham School of Nursing, Birmingham, AL

<sup>5</sup>University of South Alabama Mitchell Cancer Institute, Mobile, AL

<sup>6</sup>Institute for Human Rights, University of Alabama at Birmingham, Birmingham, AL

<sup>7</sup>Department of Health Systems and Population Health, University of Washington, Seattle, WA

<sup>8</sup>Supportive Care, Princess Margaret Cancer Centre Research Institute, Toronto, Ontario, Canada

<sup>9</sup>Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC

<sup>10</sup>University of North Carolina at Chapel Hill Department of Health Policy and Management, Chapel Hill, NC

**CORRESPONDING AUTHOR**

Gabrielle B. Rocque, MD, MSPH, University of Alabama at Birmingham, 849 Boshell Bldg 1808 7th Ave, South Birmingham, AL 35294; e-mail: grocque@uabmc.edu.

**SUPPORT**

This work was supported by the National Institute of Nursing Research (R01NR019058).

**AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

Disclosures provided by the authors are available with this article at DOI <https://doi.org/10.1200/OP.22.00360>.

**AUTHOR CONTRIBUTIONS**

**Conception and design:** All authors

**Financial support:** Gabrielle B. Rocque

**Administrative support:** Gabrielle B. Rocque, D'Ambra N. Dent, Stacey A. Ingram, Jennifer Young Pierce, Chelsea L. McGowen

**Provision of study materials or patients:** Gabrielle B. Rocque, Stacey A. Ingram, Omer Jamy, Smith Giri, Jennifer Young Pierce

**Collection and assembly of data:** Gabrielle B. Rocque, Stacey A. Ingram, Nicole E. Caston, Haley B. Thigpen, Fallon R. Lalor, Jennifer Young Pierce, Chelsea L. McGowen, Chao-Hui Sylvia Huang

**Data analysis and interpretation:** All authors

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors

**Accountable for all aspects of the work:** All authors

**REFERENCES**

1. Basch E, Deal AM, Kris MG, et al: Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial. *J Clin Oncol* 34:557-565, 2016
2. Basch E, Deal AM, Dueck AC, et al: Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. *JAMA* 318:197-198, 2017
3. Denis F, Basch E, Septans AL, et al: Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer. *JAMA* 321:306-307, 2019
4. Basch E, Stover AM, Schrag D, et al: Clinical utility and user perceptions of a digital system for electronic patient-reported symptom monitoring during routine cancer care: Findings from the PRO-TECT trial. *JCO Clin Cancer Inform* 4:947-957, 2020
5. Center for Medicare and Medicaid Services: Enhancing Oncology Care Model. <https://innovation.cms.gov/innovation-models/enhancing-oncology-model>
6. Woofter K, Kennedy EB, Adelson K, et al: Oncology Medical Home: ASCO and COA standards. *JCO Oncol Pract* 17:475-492, 2021
7. Howell D, Molloy S, Wilkinson K, et al: Patient-reported outcomes in routine cancer clinical practice: A scoping review of use, impact on health outcomes, and implementation factors. *Ann Oncol* 26:1846-1858, 2015
8. Chambers DA, Vinson CA, Norton WE: *Advancing the Science of Implementation across the Cancer Continuum*. New York, NY, Oxford University Press, 2018
9. Elwy AR, Wasan AD, Gillman AG, et al: Using formative evaluation methods to improve clinical implementation efforts: Description and an example. *Psychiatry Res* 283:112532, 2020
10. Kind AJH, Buckingham WR: Making neighborhood-disadvantage metrics accessible—The neighborhood atlas. *N Engl J Med* 378:2456-2458, 2018
11. DiMaio MBE, Denis F, Fallowfield LJ, et al: The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO clinical practice guidelines. *Ann Oncol* 33:878-892, 2022
12. National Cancer Institute: Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™), 2016. <http://healthcaresdelivery.cancer.gov/pro-ctcae/>
13. Wiltsey Stirman S, Baumann AA, Miller CJ: The FRAME: An expanded framework for reporting adaptations and modifications to evidence-based interventions. *Implement Sci* 14:58, 2019
14. Proctor E, Silmere H, Raghavan R, et al: Outcomes for implementation research: Conceptual distinctions, measurement challenges, and research agenda. *Adm Policy Ment Health* 38:65-76, 2011
15. Stover AM, Haverman L, van Oers HA, et al: Using an implementation science approach to implement and evaluate patient-reported outcome measures (PROM) initiatives in routine care settings. *Qual Life Res* 30:3015-3033, 2021
16. Vaismoradi M, Turunen H, Bondas T: Content analysis and thematic analysis: Implications for conducting a qualitative descriptive study. *Nurs Health Sci* 15: 398-405, 2013
17. Kline R, Adelson K, Kirshner JJ, et al: The Oncology Care Model: Perspectives from the Centers for Medicare & Medicaid Services and participating oncology practices in academia and the community. *Am Soc Clin Oncol Ed Book* 37:460-466, 2017
18. Patt D, Wilfong L, Hudson KE, et al: Implementation of electronic patient-reported outcomes for symptom monitoring in a large multisite community oncology practice: Dancing the Texas two-step through a pandemic. *JCO Clin Cancer Inform* 5:615-621, 2021
19. Dronkers EAC, Baatenburg de Jong RJ, van der Poel EF, et al: Keys to successful implementation of routine symptom monitoring in head and neck oncology with "Healthcare Monitor" and patients' perspectives of quality of care. *Head Neck* 42:3590-3600, 2020



**AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST****Adaptation of Remote Symptom Monitoring Using Electronic Patient-Reported Outcomes for Implementation in Real-World Settings**

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/op/authors/author-center](http://ascopubs.org/op/authors/author-center).

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](#)).

**Gabrielle B. Rocque**

This author is an Associate Editor for *JCO Oncology Practice*. Journal policy recused the author from having any role in the peer review of this manuscript.

**Consulting or Advisory Role:** Pfizer, Flatiron Health, Gilead Sciences

**Research Funding:** Carevive Systems, Genentech, Pfizer

**Travel, Accommodations, Expenses:** Gilead Sciences

**Smith Giri**

**Honoraria:** CareVive, OncLive, Sanofi

**Research Funding:** Carevive Systems, Pack Health, Sanofi (Inst)

**Doris Howell**

**Leadership:** Carevive Systems

**Consulting or Advisory Role:** Carevive

**Research Funding:** AstraZeneca (Inst)

**Ethan M. Basch**

**Consulting or Advisory Role:** SIVAN Innovation, Carevive Systems, Navigating Cancer, AstraZeneca, N-Power Medicine, Resilience Care

**Other Relationship:** Centers for Medicare and Medicaid Services, National Cancer Institute, American Society of Clinical Oncology, JAMA-Journal of the American Medical Association, Patient-Centered Outcomes Research Institute (PCORI)

**Open Payments Link:** <https://openpaymentsdata.cms.gov/physician/427875/summary>

**Angela M. Stover**

**Honoraria:** Pfizer, Association of Community Cancer Centers (ACCC), Henry Ford Health System, Purchaser Business Group on Health

**Consulting or Advisory Role:** Navigating Cancer

**Research Funding:** Urogen pharma (Inst), SIVAN Innovation (Inst)

No other potential conflicts of interest were reported.